ArticleCancer reports (Hoboken, N.J.)2026
Survival Impact of Programmed Cell Death Ligand-1 Expression in Patients With Epithelial Ovarian Carcinoma.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsTo evaluate the proportion of expressed programmed cell death ligands-1 (PD-L1) in epithelial ovarian carcinoma patients, and the association with the clinicopathological, surgical outcomes, and oncologic outcomes. To compare PD-L1 protein expression with messenger ribonucleic acid (mRNA) expression.
methodsThe patients who had pathology of epithelial ovarian/tubal/peritoneal carcinoma were enrolled. The demographic data, tumor characteristics, surgical outcomes, treatment details, and treatment response were analyzed by descriptive statistics. Spearman's rank correlation coefficient test was used to determine the correlation between protein expression and mRNA expression. The survival curve was developed utilizing the Kaplan-Meier method, the log-rank test was used to compare survival distributions of patients according to the PD-L1 protein expression.
resultsA total of 100 patients, with high-grade serous carcinoma being the most common subtype (42%). Advanced-stage disease was present in 49% of patients, and 65% achieved optimal cytoreduction. PD-L1 protein expression was detected in 23% of tumors, while the median normalized mRNA expression was 0.015 (IQR 0.004-0.037). A moderate positive correlation was observed between PD-L1 protein and mRNA expression (Spearman's rho = 0.407, p < 0.001). The mean progression-free survival (PFS) and overall survival (OS) were 44.32 ± 4.04 months and 74.19 ± 3.33 months, respectively.
conclusionsPD-L1 protein expression was observed in a minority of patients and was not significantly associated with survival outcomes. There was a moderate correlation between PD-L1 protein and mRNA expressions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.